Loading stock data…
ARS Pharmaceuticals, Inc. (SPRY)
$5.39-0.23 (-4.09%)
Market ClosedLast close Sep 8
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ARS Pharmaceuticals, Inc. in the Healthcare sector is trading at $5.39 with a market capitalization of $536M. Wall Street consensus targets $22.50 (4 analysts), implying a +317.4% move over the next 12 months. The stock is currently near its 52-week low of $4.91, remaining 37.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +317.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22.68M↓ | $28.09M↓ | $32.50M↑ | $15.72M↑ | $7.97M |
| Gross Profit | $16.39M↓ | $21.93M↓ | $24.31M↑ | $10.73M↑ | $6.88M |
| Operating Income | -$60.15M↓ | -$41.47M↑ | -$53.19M↓ | -$47.61M↓ | -$37.18M |
| Net Income | -$60.62M↓ | -$41.32M↑ | -$51.15M↓ | -$44.88M↓ | -$33.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal deliv...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$536.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1721.80%
Volume
Today's trading volume
1.09M
Recent News
ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial targeting for neffy, tighter financial discipline, and a pipeline push into chronic spontaneous urticaria. The quarter itself showed a company still early in proving […]
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 297% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of ARS Pharmaceuticals, Inc.'s Q2 2026 earnings call
ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ...
CEO Donn Casale outlines path to cash flow breakeven by 2027 while navigating slower-than-expected adoption and manufacturing headwinds.
ARS Pharmaceuticals Q2 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused promotion for its neffy intranasal epinephrine product, lower operating expenses and an expected pat